Association of Diabetes Care & Education Specialists

Login
Home Page
Your Personalized Guide
to AADE Resources
AADE GPS
My Profile
My Memberships
My Purchases
MY AADE NETWORK
My Open Invoices
Join Online
Online Store
Events
Make a Donation
Access My Learning
Access AADE7 System
Find a Diabetes Educator
Find an Accredited DSME Program
Apply For/Manage My DEAP Application
The Case Elimination Challenge: Clinical Applications for the Use of Injectable Antihyperglycemic Therapies in T2DM

The Case Elimination Challenge: Clinical Applications for the Use of Injectable Antihyperglycemic Therapies in T2DM

Quick Overview
Supported by an educational grant provided by Novo Nordisk. ...
Cart
My Cart
Availability: In stock

Price: 0.00
Required
Description

The Case Elimination Challenge: Clinical Applications for the Use of Injectable Antihyperglycemic Therapies in T2DM

Recorded Corporate Symposium
Effective dates for CE credit: 8/7/2015-8/7/2017

Program Overview

Type 2 diabetes mellitus (T2DM) is a progressive disease that frequently results in patients requiring multiple antihyperglycemic agents to achieve or maintain glycemic control. Insulin and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are among the most effective and versatile treatments available for T2DM. However, as injectable agents, they pose many challenges for healthcare professionals and patients alike. Diabetes educators are uniquely positioned to support patients with T2DM who require treatment with injectable therapy. In this interactive and engaging activity, expert faculty will represent clinical evidence encouraging the use of injectable agents across T2DM progression. Using this information, participants will collaborate in teams to develop a treatment plan for realistic case studies. Following the last presentation, the program chairperson will select the “best” treatment plan for each patient case to be discussed by the expert faculty panel.

Activity Type:

This recording of a live presentation is a knowledge-based learning activity.

Learning Objectives

At the end of this presentation, the participant will be able to:

- Assess treatment strategies that use injectable antihyperglycemic agents to individualize treatment for patients with T2DM based on current patient-centered guidelines
- Evaluate outcomes in patients using GLP-1 RAs, either alone or in combination with other antihyperglycemic agents, including insulin, across T2DM progression
- Review strategies to address and overcome barriers to injectable agents used alone or in combination to manage T2DM across the progression of the disease

Agenda

- Faculty introductions and format explanations
- Case collaboration and “working case” development
- Overview of treatment current guidelines (ADA/EASD and AACE)
- Case collaboration and “working case” development
- Using GLP-1 RA therapy in T2DM
- Case collaboration and “working case” development
- Using insulin therapy in T2DM
- Case collaboration and “treatment plan” development
- Using GLP-1 RAs and insulin therapy in combination in T2DM
- Faculty discussion of 3 selected cases
- Question-and-answer session

Intended Audience

This is a knowledge-based activity designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, MDs, and other health care providers interested in staying up to date on current practices of care for their patients with diabetes and other related conditions.

Faculty

Geralyn Spollett, MSN, ANP-CS, CDE
Associate Director & Adult Nurse Prectitioner
Yale Diabetes Center

Richard Pratley, MD
Samuel E. Crockett MD Chair in Diabetes Research - Director
Florida Hospital Diabetes Institute

Jay Shubrook, DO, FACOFP, FAAFP, BC-ADM
Professor, Director of Diabetes Services, Director of Clinical Research
Touro University California - College of Osteopathic Medicine

Support

This program is supported by an educational grant provided by Novo Nordisk.

Continuing Education Credit

This educational program will provide 1.5 contact hours of continuing education credit. To successfully complete the program to earn CE credit, learners must view the recorded session in its entirety, complete any associated assessment activities, and submit an evaluation survey. A continuing education statement of credit will be provided online.

Accreditation Information

Registered Nurses

The American Association of Diabetes Educators is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational program will provide 1.5 contact hours of continuing education credit.

AADE is accredited as a provider of continuing nursing education by the California Board of Registered Nursing (CEP # 10977).

Registered Dietitians

The American Association of Diabetes Educators, (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.

Registered Pharmacists

The American Association of Diabetes Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This program provides 1.5 contact hours (0.15 CEUs) of continuing education credit.

ACPE Universal Program Number: 0069-9999-15-192-H01-P
Effective Dates: 8/7/2015 – 8/7/2017

Faculty Disclosures

It is the policy of the American Association of Diabetes Educators to require that anyone who has an opportunity to affect continuing education activities content (e.g. authors, presenters and program planners) with products or services from a commercial interest with which s/he has financial relationships, discloses those financial relationship/s with commercial entities to participants.

Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Relevant disclosures (or lack thereof) among educational activity faculty and planners are as follows:
- Geralyn Spollett, MSN, ANP-CS, CDE, Yale Diabetes Center, has no relevant financial disclosures to report.
- Richard Pratley, MD, Florida Hospital Diabetes Institute, is Research Grant at Gilead Sciences, Lilly, Merck, Novo-Nordisk, Sanofi-Aventis US LLC, Takeda; Speaker for AstraZeneca and Novo-Nordisk; Honoraria from Novo-Nordisk; Consultant at AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Hanmi Pharmaceutical Co. Ltd, Merck, Novo-Nordisk, Takeda.
- Jay Shubrook, DO, FACOFP, FAAFP, BC-ADM, Touro University California - College of Osteopathic Medicine, is Research grant at Sanofi-Aventis; Consultant for Eli Lilly, Novo-Nordisk, AstraZeneca.
- Katie Fidanza, Institute for Medical and Nursing Education, Atlanta, GA, has no relevant financial disclosures to report.
- Nancy Stonis, AADE, Chicago, IL, has no relevant financial disclosures to report.
- Jackie Bellan, AADE, Chicago, IL, has no relevant financial disclosures to report.
- Leah Johnson, AADE, Chicago, IL, has no relevant financial disclosures to report.

The approval of this educational offering by the AADE does not imply endorsement of specific therapies, treatments, or products discussed in the presentations.

Originally presented on: 8/7/2015
Expiration date: 8/7/2017

Access Period

You will have access to this learning activity for a period of six months after you enroll, or whenever the activity's CE credits expire (whichever comes first).

Price

Members: $0.00
Non-Members: $45.00


We're sorry, but there is no inventory for the product you selected. Check out these other great products:

Related Items

    Products Others Bought

      Reviews
      No records found.